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Background. The rapidly growing field of targeted tumor therapy often utilizes an antibody, sometimes tagged with a tumor-
ablating material such as radioisotope, directed against a specific molecule. Methodology/Principal Findings. This report
describes the discovery of nine novel decapeptides which can be radioactively labeled, bind to, and deliver
32P to colon cancer
cells. The decapeptides vary from one another by one to three amino acids and demonstrate vastly different binding abilities.
The most avidly binding decapeptide can permanently deliver very high levels of radioisotope to the adenocarcinoma cancer
cell lines at an efficiency 35 to 150 times greater than to a variety of other cell types, including cell lines derived from other
types of cancer or from normal tissue. Conclusions/Significance. This experimental approach represents a new example of
a strategy, termed peptide binding therapy, for the potential treatment of colorectal and other adenocarcinomas.
Citation: Abraham JM, Sato F, Cheng Y, Paun B, Kan T, et al (2007) Novel Decapeptides that Bind Avidly and Deliver Radioisotope to Colon Cancer
Cells. PLoS ONE 2(10): e964. doi:10.1371/journal.pone.0000964
INTRODUCTION
Illness and death due to colorectal and esophageal cancer
constitute a monumental health care challenge in the United
States and throughout the world [1,2]. Current treatments include
radiotherapy, surgery, and chemotherapy. There are a number of
immunotherapies approved for use in the treatment of various
types of cancers (e.g., Herceptin, Rituxin, Avastin, and others) [3–
6]. All of these immunotherapies utilize a monoclonal antibody
directed against a specific cellular molecule [7,8]. Destructive
action against tumor cells is thought to involve ADCC (antibody-
dependent cellular cytotoxicity), cellular lysis via the complement
pathway, or the induction of apoptosis [9,10]. Avastin is a mono-
clonal antibody directed against VEGF (vascular endothelial
growth factor) and is approved for treatment of colorectal cancer
[11–13].
In addition, Non-Hodgkins lymphoma (NHL) is currently
treated with two approved radioimmunotherapeutic regimens:
Bexxar and Zevalin. Both utilize a monoclonal antibody directed
against the B-cell marker CD20 and can deliver either
131I
(Bexxar) or
90Y (Zevalin) isotopes to target lymphoma cells
[14,15]. Beta-particles (electrons) generated by these isotopes can
deeply penetrate cells and damage DNA, leading to cell death.
However, there are currently no radioimmunotherapies approved
for the treatment of patients with colorectal cancer.
The decapeptides described herein bind to and transfer isotope
(
32P) to cell lines derived from several colorectal carcinomas.
Under identical experimental conditions, very little (viz., less than
1% of the colon cancer cell lines’ rates) of the most efficient
32P-
labeled decapeptides bind to cell lines established from a variety of
other cancers or to normal colon, kidney, or esophageal cells.
RESULTS
We have identified nine decapeptides, differing from one another
by only a few amino acids, that when labeled with
32P can bind to
a number of colorectal carcinoma cell lines. All decapeptides
contain a protein kinase A substrate sequence and are designated
as MAs (Modified Adjuvant). Figure 1 is a schematic represen-
tation of the production of the
32P-labeled peptides and the
experimental design of assays to measure binding of peptides to
cell lines.
Figure 2 displays the number of
32P counts per minute (cpm)
remaining bound to eighteen different cell lines and blank wells
after a two hour incubation with MA5, the most efficient binding
decapeptide (see below). The Caco-2 colon adenocarcinoma cell
line retained the greatest number of radioactive counts after a two-
hour incubation and subsequent washes with complete medium,
the average value of triplicate wells equaling 298,639 cpm per
10,000 cells. HCT116 colon adenocarcinoma cells retained an
average value of 131,998 cpm per 10,000 cells. Blank wells and
nonbinding cell lines had mean values of less than 550 cpm; bars
representing these values are not visible at the scale used in
Figure 2. For example, HeLa S3 cervical cancer cells only
retained an average of 534 cpm per 10,000, HT1080 fibrosarco-
ma cells retained 367 cpm, and the human embryonic kidney cell
line 293H retained 429 cpm per 10,000 cells.
Seven of the eighteen cell lines demonstrated very strong
retention of radioactivity when incubated with MA5 (Modified
Adjuvant radioactive peptide) with five of these being colon
adenocarcinoma cell lines (Caco-2, HCT15, HCT116, LoVo,
HT29), one being an esophageal adenocarcinoma cell line (SEG1),
and one being a Barrett’s esophagus cell line (QHTRT). In
contrast, the eleven nonbinding cell lines were mostly squamous
cell lines derived from carcinomas of the cervix (HeLa S3), colon
(RKO), lung (1271, A549), esophagus (KYSE-70), a fibrosacroma
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(1459), or esophagus (HEEpiC). Nonbinding cell lines included
T84, derived from a colon adenocarcinoma metastatic to lung,
and SK-BR-3, isolated from a breast adenocarcinoma. The ratio
of cpm retained by Caco-2 (298,639) to the average of the eleven
nonbinding cell lines (365) was 818:1. Caco-2 cells retained
approximately 18% of the total radioactive counts present in the
incubation well after two-hour incubation.
Nine MA variants were assayed for adherence to Caco-2 cells
after two hours’ incubation. The relative binding level and amino
acid composition of each MA variant is displayed in Figure 3A.
Alteration of only one to three amino acids within the peptide
resulted in retention differences as large as 70-fold, e.g., in variant
MA2 vs. variant MA5.
To investigate how quickly
32P isotope could be transferred
from the peptide variants and incorporated into cellular proteins,
the three most avidly binding MAs (see Figure 3A) were added to
replicate wells containing Caco-2 cells, then washed away at
varying time intervals and the cells and supernatant assayed. As
shown in Figure 3B, substantial percentages of these
32P-labeled
variant decapeptides bound to cells within only a few minutes,
with large amounts of radiolabeled cellular proteins appearing at
two hours after exposing cells to the labeled peptides. Notably,
a parallel experiment in which conditions described in Figure 3
were duplicated, but washed cells were incubated overnight in
complete medium (data not shown), still revealed similar levels of
32P-decapeptide release and retention for all nine MAs, as
described for MA5 in Figure 2.
The peptide binding, washing and assay experiment described
for Figure 2 was then repeated in the seven most avidly binding
cell lines using MA5, except that after three washes of medium,
200 ul of complete medium was added to each well and the cells
were incubated overnight at 37uC. Figure 4A shows the cpm
Figure 1. Schematic diagram of experimental approach. A bacterial
recombinant expression system produced various gluthathione-S-
transferase decapeptide fusion proteins which were bound to
gluthatione and labeled with
32P utilizing protein kinase A. After
washing, the labeled decapeptides were recovered after thrombin
digestion and incubated at various times with several different cell lines.
doi:10.1371/journal.pone.0000964.g001
Figure 2. Levels of binding of decapeptide MA5 to eighteen different cell lines.The
32P labeled decapeptide MA5 was incubated for two hours with
10,000 cells, washed three times, and the radioactive counts of the cells determined by scintillation counting. Seven cell lines demonstrated avid
binding of MA5 and are shown as bar graphs of the mean and one standard deviation in triplicate wells. The remaining eleven cell lines, along with
one blank well averaged only 365 cpm. These values are so small as to not be visible at the scale used in this figure. Further information on the
individual cell lines is provided in the Supplemental Information.
doi:10.1371/journal.pone.0000964.g002
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incubation. Approximately 88% of MA5 radioactive counts
initially retained by the colon cancer cell lines was released into
the medium, while approximately 12% of initially retained
radioactive counts were retained by cells. The two esophageal
cell lines that originally retained large amounts of radioactive
counts, QH-TRT and SEG1, retained 39% and 37% of their
original counts, respectively, after overnight incubation. Caco-2
cells retained the greatest number of counts, averaging
58,305 cpm in triplicate wells containing 10,000 cells each. This
figure represents approximately 5.8 cpm, or 348 counts per hour,
per cell (i.e., when extrapolated over a potential 2-week exposure
period, equivalent to over 87,000 counts per cell).
Figure 4B shows the time course of the release of MA5 from
the Caco-2 adenocarcinoma cell line over a 48-hour time period.
The majority of the total counts released over the 48 hour time
period are released by nine hours of incubation. Figures 4C and
4D consist of two autoradiograms showing the locations of the
radioactive molecules described in Figure 4B on polyacrylamide-
SDS gels. The sizes of the cellular radioactive proteins in the cells
are shown in Figure 4C;
32P-labeled MA5 released into the
medium is shown in Figure 4D. There is apparent agreement on
the distribution and overall radioactivity levels in comparing
Figure 4B and Figures 4C and 4D. As soon as two hours after
the introduction of the radioactive peptide, a substantial portion of
the isotope appears to have been transferred to higher molecular
weight proteins.
DISCUSSION
This report describes the discovery of decapeptides that can be
labeled with a high energy (1.7 Mev) beta emitter (
32P) and can
bind avidly to several different adenocarcinoma cell lines,
efficiently delivering this potential tumor-ablating material to the
cells. The decapeptides, termed MA for Modified Adjuvant, are
protein kinase substrates. Previously, it had never been shown or
suspected that this substrate, when labeled with a tumor-ablating
material such as
32P, could bind to and transfer the radioisotope to
a cell line after one to two hours of incubation. Moreover, we have
shown for the first time that transfer of isotope from these
decapeptides is restricted to cell types derived from primary colon
and esophageal adenocarcinomas. For example, exposure of
certain colon cancer cell lines (e.g. Caco-2) to the most avidly
binding labeled peptide, MA5, for a two-hour period resulted in
the transfer of a radioactive dose of over 29 counts per minute per
cell after a two hour incubation, wash, and immediate de-
termination of the retained radioactivity.
The incubation of
32P-labeled decapeptide with certain cell lines
resulted in large amounts of peptide being retained after a two-
hour incubation, but a substantial proportion of this bound
peptide was released after an overnight incubation. For example,
after incubation of the labeled variant MA5 with Caco2 cells for
two hours, three wash steps, and overnight incubation in medium,
88% of the originally retained
32P isotope was released. However,
the 12% that was retained by cells still represented 5.8 cpm per
cell, extrapolating to over 8,300 counts per cell per day. In
addition, radioactivity that was still retained by cells after
overnight medium incubation was permanently incorporated into
a variety of cellular proteins, as demonstrated by polyacrylamide
gel electrophoresis of post-exposure cellular lysates
Among 18 cell lines assayed for their ability to bind the
decapeptides, seven demonstrated very high retention of isotope
after two-hour incubation. Although all seven of these lines
released from 63% to 88% of this radioactivity after an overnight
incubation, the amount of isotope that was retained overnight was
still substantial. Of these seven cell lines, five were derived from
colorectal adenocarcinomas, one from an esophageal adenocarci-
noma, and one from a Barrett’s metaplasia specimen. The 11 cell
lines that did not bind the radioactively labeled decapeptide MA5
Figure 3. Relative levels of binding of nine
32P-labeled decapeptide variants. (A) Nine
32P-labeled different decapeptides, varying from one
another by only one to three amino acids, were incubated with Caco-2 cells for two hours, the cells washed three times, and counts remaining bound
to the cells are shown as a percentage of the total amount of counts for each decapeptide used. Amino acid substitutions for each variant (relative to
MA1) are underlined and bolded. (B) The variants, MA1, MA4, and MA5 were incubated with Caco-2 cells for intervals varying from five minutes to
two hours, washed, the adherent cells dissolved in gel loading buffer and an aliquot run on a 10%–20% gradient polyacrylamide-SDS gel. The three
lanes marked ‘‘24h’’ (lanes 5, 10, and 15) were incubated with the respective labeled decapeptides (MA1, MA4, MA5) for two hours, washed, and the
cells incubated with complete medium for 24 hours. The cells were treated as described for the other lanes of this figure.
doi:10.1371/journal.pone.0000964.g003
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squamous cell carcinomas of the cervix, lung, breast, and
a fibrosarcoma, as well as normal kidney, colon, and esophageal
tissues.
The majority of approved immunotherapeutic regimens for
cancer involve an antibody directed against a specific cellular
molecule [16]. These agents can function by binding to the cell
surface and may utilize ADCC, complement activation, or cellular
apoptosis. The antibodies may also be coupled to a tumor-ablating
agent, such as toxins or radioisotopes [17-21]. The addition of
isotope to peptides, and their use for both diagnostic and
therapeutic purposes, is an active area of biomedical research
[22-25]. Our work utilizes protein kinase A substrates labeled with
32P isotope. A high-energy beta-emitting radioisotope results in an
electron pathlength range of up to 5 mm, permitting substantial
penetration of solid tumors. Due to a predicted ‘‘bystander’’ effect,
one beta particle will penetrate hundreds or thousands of cells
within the tumor, even those not directly binding the decapeptide.
Moreover, since the molecular weights of these minuscule
decapeptides proteins are far lower than the exclusionary
molecular weight limit of the filtering kidneys, these peptides
should be rapidly eliminated in the urine, leading to reduced
systemic toxicity. Thus, it should be feasible for both a radioactive
dose and unbound radioactivity to be eliminated easily and in
a relatively short period of time. We anticipate that additional
known enzyme substrates may eventually be identified as potential
vehicles for the specific delivery of anti-tumor agents to cancer
cells and that potential cancer therapeutic regimens employing this
peptide or other similar substances might be the newest strategy
for peptide binding therapy.
MATERIALS AND METHODS
Production of the
32P-labeled decapeptides: Different DNA
oligomers were cloned into pGEX-4T-1 (GE Healthcare) which
yield various decapeptides after thrombin cleavage designated
MA1 through MA9 (Modified Adjuvant). The protein sequences
are: MA1, GSRRASVGSA; MA2, GSRGASVGGA; MA3,
GSRRGSVGSA; MA4, GSRRGSVASA; MA5, GSRRASVASA;
MA6, GSRRASVGSG; MA7, GSRGGSVGSA; MA8,
GSRGGSVASA; MA9, GSRGGSVGSG. DH5-a bacteria con-
Figure 4. The majority of the
32P-labeled decapeptide MA5-bound molecules are released from Caco-2 cells. (A) The
32P-labeled decapeptide
MA5 was incubated for two hours with seven different cell lines, the cells were washed, and complete medium was added. Following a 24 hour
incubation, the number of counts per minute released into the medium (R) as well as the number of counts remaining bound to the cells (B) were
determined. Each bar shows the mean and one standard deviation of triplicates wells. (B) Time course for the release and retention of the
32P-labeled
decapeptide MA5. MA5 was incubated for two hours with Caco-2 cells, the cells washed, and the cpm released (dashed line) as well as remaining
bound (solid line) to the cells determined for time intervals post-washing. Each point shows the mean plus/minus one standard deviation of triplicate
determinations. C) Radioactive well contents described as bound (solid line) in Figure 4B were run on a 16.5% polyacrylamide-SDS gel and exposed
to film. Immediately after washing (i.e., at 0 hours), the majority of the counts were visualized as
32P-peptide. Over the next 48 hours, the peptide
counts greatly diminished, with the majority of bound radioactivity incorporated into cellular proteins. (D) Aliquots of medium containing the
released (dotted line)
32P-peptide MA5 were assayed at time intervals after washing, as described in Figure 4B. As time progressed, more of the
32P-
peptide was released, reaching a plateau by 24 hours after washing.
doi:10.1371/journal.pone.0000964.g004
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100 mg/ml ampicillin), diluted 1/10 in LB-Amp and grown at
37uC for two hours. IPTG was added to 1 mM and the culture
grown at 37uC for five hours. Ten ml of each culture were
centrifuged and the cell pellet resuspended in 1 X TBS containing
100 mg/ml lysozyme. After two cycles of freeze-thaw, the lysate
was centrifuged and the supernatant was mixed with 100 mlo f
Sepharose-Glutathione for two hours at RT. Each pellet was
washed three times with 1 X TBS, and the bound recombinant
fusion proteins were labeled with
32P using protein kinase A and
32P-c-ATP according to the manufacturer’s instructions (Sigma,
St. Louis, Mo.). The pellet was washed four times with 1 X PBS
and the labeled decapeptide was cleaved and released into the
supernatant with thrombin (GE Healthcare).
Assay of the binding of
32P-labeled decapeptides to cell lines:
Cell lines were grown in complete medium containing 10% bovine
fetal serum (heat inactivated). In each well of a 96-well plate,
10,000 cells from various cell lines were grown overnight in
complete medium. Ten ml of the labeled-peptide in 1 X PBS and
90 ml of complete medium were added to each well and incubated
at 37uC at various times of up to two hours. The peptide-medium
was removed and one ml added to 100 ul gel loading buffer and
counted by scintillation counting for the probe control or run on
a polyacrylamide-SDS gel (Biorad).The adherent cells were briefly
and gently washed with complete medium three times and some
wells were assayed immediately by adding 100 ml of gel loading
buffer to each well and run on a gel or counted in a scintillation
counter. Other wells had 100 ml complete medium added and
incubated for a further time period. Samples were either counted
in a liquid scintillation counter or run on polyacrylamide-SDS
gels, exposed to x-ray film, and the film developed.
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